AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Arrivent: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $40
ByAinvest
Tuesday, Jul 22, 2025 8:00 am ET1min read
HC Wainwright & Co. reiterates 'Buy' rating on Arrivent(AVBP).
The target price is unchanged and still at 40 .
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-22 | HC Wainwright & Co. | Reiterates | Buy | Buy | $40 | $40 |
| 2025-07-10 | Goldman Sachs | Reinstates | Buy | -- | $33 | $-- |
| 2025-06-25 | Clear Street | Initiates Coverage On | Buy | -- | $32 | $-- |
| 2025-06-24 | Guggenheim | Reiterates | Buy | Buy | $45 | $45 |
| 2025-06-24 | Oppenheimer | Maintains | Outperform | Outperform | $44 | $39 |
[Recent Earning Results] Arrivent posted the Q1 of its 2025 financial results on 5/12/2025, reporting net income of USD -64.39 million in the first quarter, expanding 269.68% from USD -17.42 million year over year.
[Company Profile] Arrivent Biopharma, Inc. was incorporated under the laws of the State of Delaware on April 14, 2021. The company is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company seek to utilize team’s deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet